Apr 13, 2016

Posted by in Biotech Stocks | 0 Comments

Trader’s Watch List: Grifols SA, Barcelona (NASDAQ:GRFS), Synthetic Biologics Inc (NYSEMKT:SYN), Alexion Pharmaceuticals Inc (NASDAQ:ALXN)

Trader’s Watch List: Grifols SA, Barcelona (NASDAQ:GRFS), Synthetic Biologics Inc (NYSEMKT:SYN), Alexion Pharmaceuticals Inc (NASDAQ:ALXN)

Grifols SA, Barcelona (NASDAQ:GRFS) stock is at $15.46, down -0.13 percent from its previous close of $15.48. The stock opened the session at $15.32 and touched its highest price point at $15.46. The company’s stock’s lowest price point for the session stood at $15.20. Its yesterday’s volume was 1.53 million shares in comparison to its usual trading volume of 1.47 million shares.

Grifols SA, Barcelona (NASDAQ:GRFS), a biopharmaceutical company, develops, manufactures, and distributes plasma derivative products in the United States, Canada, Spain, rest of the European Union, and internationally. It specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation, and reagents for use in hospitals and clinics. The company operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, which include IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. I

Synthetic Biologics Inc (NYSEMKT:SYN) stock is at $2.37, up +1.28 percent from its previous close of $2.37. Its yesterday’s volume was 1.50 million shares in comparison to its usual trading volume of 835,920.00 shares. Previous 5 days graph demonstrated a negative move of -8.14%. Its quarterly performance remained green with the percentage of 44.51, while its year to date performance showed that the stock advanced overall 4.87%.

Synthetic Biologics Inc (NYSEMKT:SYN) on March 10, 2016 reported financial results for the year ended December 31, 2015.

General and administrative expenses were $8.1 million for the year ended December 31, 2015, compared to $6.0 million for the same period in 2014. This increase was primarily the result of increased employee costs, audit fees related to additional procedures required under the accelerated filer status, legal fees associated with SEC filings and collaborative agreements, and stock-based compensation expense. Non-cash charges related to stock-based compensation were $2.1 million for the year ended December 31, 2015, compared to $1.6 million for the same period in 2014.

Research and development expenses increased to $32.9 million for the year ended December 31, 2015, from $14.5 million for the same period in 2014. This increase of 127% was primarily the result of increased program costs associated with expanded clinical development, manufacturing and research activities within our microbiome-focused pipeline, including the Company’s Phase 2 C. difficile and IBS-C clinical programs. In August 2015, Synthetic Biologics entered into an Exclusive Channel Collaboration (ECC) with Intrexon Corporation for the development of a treatment for patients with phenylketonuria (PKU) and issued 937,500 shares of common stock to Intrexon as payment of the technology access fee, which resulted in a non-cash charge of $3.0 million. Research and development expenses also included a $1.0 million non-cash expense for achieving the third milestone set forth in the Prev ABR LLC agreement with regard to the Company’s C. difficile program. Non-cash charges related to stock-based compensation were $1.1 million for the year ended December 31, 2015, compared to $803,000 for the same period in 2014.

Other income was $3.8 million for the year ended December 31, 2015, compared to other income of $718,000 for the same period in 2014. Other expense for the year ended December 31, 2015 was primarily due to non-cash expense of $3.8 million from the change in fair value of warrants. The increase in fair value of the warrants was due to the increase in our stock price from the year ended December 31, 2014.

Alexion Pharmaceuticals Inc (NASDAQ:ALXN) traded in the range of $147.87 and $153.91 in its previous trading session. The stock recorded the volume of 1.46 million shares so far, in comparison its average daily trading volume of 1.77 million shares. Company’s year to date performance remained declining as it lost almost -19.74%. The stock opened at $148.49 and its closing price for the day was $153.91, up +3.83 percent from its previous close.

Alexion Pharmaceuticals Inc (NASDAQ:ALXN) on April 12, 2016 announced that the Company will report its financial results for the first quarter ended March 31, 2016 on Thursday, April 28, 2016 before the US financial markets open. Following the release of the financial results, Alexion management will conduct a conference call and audio webcast on Thursday, April 28, 2016, at 10:00 a.m. Eastern Time (ET).

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency.

 

Comments are closed.